Cargando…

‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’

PURPOSE OF REVIEW: Explore whether immunization with germline-targeting Env immunogens during ART, followed by ATI, leads to the identification of viral envelope glycoproteins (Envs) that promote and guide the full maturation of broadly neutralizing antibody responses. RECENT FINDINGS: The HIV-1 env...

Descripción completa

Detalles Bibliográficos
Autor principal: Stamatatos, Leonidas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552831/
https://www.ncbi.nlm.nih.gov/pubmed/37712859
http://dx.doi.org/10.1097/COH.0000000000000817
_version_ 1785116040897757184
author Stamatatos, Leonidas
author_facet Stamatatos, Leonidas
author_sort Stamatatos, Leonidas
collection PubMed
description PURPOSE OF REVIEW: Explore whether immunization with germline-targeting Env immunogens during ART, followed by ATI, leads to the identification of viral envelope glycoproteins (Envs) that promote and guide the full maturation of broadly neutralizing antibody responses. RECENT FINDINGS: The HIV-1 envelope glycoprotein (Env) does not efficiently engage the germline precursors of broadly neutralizing antibodies (bnAbs). However, Env-derived proteins specifically designed to precisely do that, have been recently developed. These ‘germline-targeting’ Env immunogens activate naïve B cells that express the germline precursors of bnAbs but by themselves cannot guide their maturation towards their broadly neutralizing forms. This requires sequential immunizations with heterologous sets of Envs. These ‘booster’ Envs are currently unknown. SUMMARY: Combining germline-targeting Env immunization approaches during ART with ATI could lead to the identification of natural Envs that are responsible for the maturation of broadly neutralizing antibody responses during infection. Such Envs could then serve as booster immunogens to guide the maturation of glBCRs that have become activated by germline-targeting immunogens in uninfected subjects.
format Online
Article
Text
id pubmed-10552831
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-105528312023-10-06 ‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’ Stamatatos, Leonidas Curr Opin HIV AIDS IS AN HIV VACCINE STILL ACHIEVABLE?: Edited by Jim Kublin PURPOSE OF REVIEW: Explore whether immunization with germline-targeting Env immunogens during ART, followed by ATI, leads to the identification of viral envelope glycoproteins (Envs) that promote and guide the full maturation of broadly neutralizing antibody responses. RECENT FINDINGS: The HIV-1 envelope glycoprotein (Env) does not efficiently engage the germline precursors of broadly neutralizing antibodies (bnAbs). However, Env-derived proteins specifically designed to precisely do that, have been recently developed. These ‘germline-targeting’ Env immunogens activate naïve B cells that express the germline precursors of bnAbs but by themselves cannot guide their maturation towards their broadly neutralizing forms. This requires sequential immunizations with heterologous sets of Envs. These ‘booster’ Envs are currently unknown. SUMMARY: Combining germline-targeting Env immunization approaches during ART with ATI could lead to the identification of natural Envs that are responsible for the maturation of broadly neutralizing antibody responses during infection. Such Envs could then serve as booster immunogens to guide the maturation of glBCRs that have become activated by germline-targeting immunogens in uninfected subjects. Lippincott Williams & Wilkins 2023-11 2023-09-08 /pmc/articles/PMC10552831/ /pubmed/37712859 http://dx.doi.org/10.1097/COH.0000000000000817 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle IS AN HIV VACCINE STILL ACHIEVABLE?: Edited by Jim Kublin
Stamatatos, Leonidas
‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’
title ‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’
title_full ‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’
title_fullStr ‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’
title_full_unstemmed ‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’
title_short ‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’
title_sort ‘immunization during art and ati for hiv-1 vaccine discovery/development’
topic IS AN HIV VACCINE STILL ACHIEVABLE?: Edited by Jim Kublin
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552831/
https://www.ncbi.nlm.nih.gov/pubmed/37712859
http://dx.doi.org/10.1097/COH.0000000000000817
work_keys_str_mv AT stamatatosleonidas immunizationduringartandatiforhiv1vaccinediscoverydevelopment